Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5D

Wang, Xuerong; Liu, Yuan; Zhang, Jingjing; Hao, Li; Wang, Deguang

doi:10.1111/nep.12813

Cited by 39 publications

(31 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, despite the predictive ability of sclerostin for all-cause mortality in the current study, serum sclerostin was not associated with cardiovascular mortality, which differs from the independent relationship between sclerostin and cardiovascular mortality revealed by a previous result [ 29 ]. The discrepancy of the results may be attributable to the difference in demographic characteristics, considering that patients with chronic kidney disease were enrolled in the previous study and we focused on elderly SCAD patients with normal renal function.…”

Section: Discussioncontrasting

confidence: 99%

Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention

Chen

et al. 2019

Aging Clin Exp Res

View full text Add to dashboard Cite

Background Recently, sclerostin, a bone-derived protein, has been shown to play a key role in atherosclerosis progression. However, few studies have investigated the influence of sclerostin on cardiovascular disease prognosis. We investigated the relationship between serum sclerostin levels and adverse outcomes in elderly patients with stable coronary artery disease (SCAD) who were undergoing percutaneous coronary intervention (PCI). Methods We enrolled 310 elderly SCAD patients who underwent PCI in this study and followed them 3 years. According to the median serum sclerostin levels, subjects were stratified into a low sclerostin (low scl) group (n = 144) and a high sclerostin (high scl) group (n = 166). Time-to-event analyses were performed with the Kaplan-Meier method. Associations between sclerostin levels and main adverse cardiovascular and cerebrovascular events (MACCEs) and mortality were evaluated by Cox multivariate regression analysis. The prognostic power of predictive models was verified by the concordance index and receiver operating characteristic curve analysis. Results The high scl group had a significantly higher MACCE-free rate and better survival than the low scl group. Serum sclerostin was an independent predictor and could improve the prognostic power for adverse outcomes. In addition, serum sclerostin levels were significantly associated with bone turnover markers, a lower presence of multivessel disease and a lower CCS angina class. Conclusions Serum sclerostin is a prognostic parameter for predicting and intervening in the adverse outcomes of elderly SCAD patients undergoing PCI, which may be explained by its potential role in the bone-vascular axis.

show abstract

Section: Discussioncontrasting

confidence: 99%

Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention

Chen

et al. 2019

Aging Clin Exp Res

View full text Add to dashboard Cite

show abstract

“…After vascular calcification has progressed, serum sclerostin is elevated to decrease β-catenin stability in the cells and suppress the proliferation and differentiation of osteoprogenitor cells [ 15 , 16 , 37 ]. Clinical studies have reported that serum sclerostin levels are positively correlated with carotid intima-media thickness in hemodialysis patients, and positively associated with coronary artery or abdominal aortic calcification in non-dialysis CKD patients [ 40 – 42 ]. Moreover, serum sclerostin levels were found to be positively associated with brachial-ankle PWV values in kidney transplantation patients, and positively associated with cfPWV values in chronic kidney disease (CKD), hemodialysis, and postmenopausal women [ 20 , 43 – 45 ].…”

Section: Discussionmentioning

confidence: 99%

Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients

Chang

Hsu

Liou

et al. 2018

BMC Cardiovasc Disord

View full text Add to dashboard Cite

BackgroundSclerostin is known to be a canonical Wnt/β-catenin signaling pathway inhibitor, while the Wnt/β-catenin signaling pathway is proposed to be involved in the development of arterial stiffness. This study aims to investigate the relationship between serum sclerostin levels and carotid–femoral pulse wave velocity (cfPWV) among hypertensive patients.MethodsFasting blood samples were obtained from 105 hypertensive patients. Patients with cfPWV values of > 10 m/s were classified in the high arterial stiffness group, whereas those with cfPWV values of ≤10 m/s were assigned to the low arterial stiffness group. Serum sclerostin and Dickkopf-1 (DKK1) levels were quantified using commercially available enzyme-linked immunosorbent assays.ResultsThirty-six hypertensive patients (34.3%) who belonged to the high arterial stiffness group were generally older (p < 0.001), presented with lower estimated glomerular filtration rates (eGFR, p = 0.014), higher incidence of diabetes mellitus (p = 0.030), average systolic blood pressures (SBP, p = 0.013), pulse pressure (p = 0.026), serum creatinine levels (p = 0.013), intact parathyroid hormone levels (iPTH, p = 0.003), and sclerostin levels (p < 0.001) than their counterparts in the low arterial stiffness group. A multivariable logistic regression analysis identified sclerostin as an independent predictor of arterial stiffness in hypertensive patients (odds ratio, 1.042; 95% confidence interval (CI), 1.017–1.068; p = 0.001). Multivariable forward stepwise linear regression analysis also showed that serum sclerostin level (β = 0.255, adjusted R2 change: 0.146, p = 0.003) was positively associated with cfPWV values in patients with hypertension.ConclusionsIn this study, serum sclerostin level, but not DKK1, is found to be positively correlated with cfPWV values and is identified as an independent predictor of arterial stiffness in hypertensive patients after adjusting for significant confounders.

show abstract

“…Sclerostin has been reported to be involved in macrovascular development [225]. Serum sclerostin levels have also been reported to correlate with the calcification of the abdominal aorta in patients with chronic kidney disease [226]. Alternatively, there is a report that survival prognosis in dialysis patients is not correlated with serum sclerostin levels [227], and the effect of sclerostin on the vasculature is controversial.…”

Section: Future Direction and Conclusionmentioning

confidence: 99%

The Regulation of Bone Metabolism and Disorders by Wnt Signaling

Maeda

Kobayashi

Koide

et al. 2019

IJMS

250

240

View full text Add to dashboard Cite

Wnt, a secreted glycoprotein, has an approximate molecular weight of 40 kDa, and it is a cytokine involved in various biological phenomena including ontogeny, morphogenesis, carcinogenesis, and maintenance of stem cells. The Wnt signaling pathway can be classified into two main pathways: canonical and non-canonical. Of these, the canonical Wnt signaling pathway promotes osteogenesis. Sclerostin produced by osteocytes is an inhibitor of this pathway, thereby inhibiting osteogenesis. Recently, osteoporosis treatment using an anti-sclerostin therapy has been introduced. In this review, the basics of Wnt signaling, its role in bone metabolism and its involvement in skeletal disorders have been covered. Furthermore, the clinical significance and future scopes of Wnt signaling in osteoporosis, osteoarthritis, rheumatoid arthritis and neoplasia are discussed.

show abstract

Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5D

Cited by 39 publications

References 25 publications

Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention

Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention

Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients

The Regulation of Bone Metabolism and Disorders by Wnt Signaling

Contact Info

Product

Resources

About